Parkinson's Disease CME

Hardware and Software Specifications Needed to View

This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.

Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be Macromedia Flash Player, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

CME Information

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and MedThink Communications, Inc. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

CME Credit Statement

The EOCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity.

The faculty of this CME activity disclose the following:

Ron Miller, PhD, educational reviewer, has nothing to disclose.

Robert Hauser, MD, discloses the following:

Type of Relationship	Company
Advisory Board	Allergan Sales, LLC; Bayer Schering Pharma AG; Boehringer Ingelheim France; Cephalon, Inc; Eisai Limited; Elan Pharmaceuticals; GlaxoSmithKline; Impax Laboratories, Inc; Kyowa Pharmaceutical, Inc; Merck KgaA; National Institute of Health; Norvartis Pharmaceutical Corporation; Pharmacia; Schwarz Pharma; Solvay Pharmaceuticals; Teva Neuroscience; Vernalis; XenoPort, Inc
Consultant	Allergan Sales, LLC; Bayer Schering Pharma AG; Bioavail Pharmaceuticals, Inc; Boehringer Ingelheim France; CombinatoRx; Eisai Limited; EMD Serono, Inc; Genzyme Corporation; GlaxoSmithKline; HealthCare Research and Consulting; Impax Laboratories, Inc; Kyowa Pharmaceutical, Inc; Novartis Pharmaceutical Corporation; Ortho-McNeill Janssen Scientific Affairs; Prestwick Pharmaceuticals, Inc; Schering Plough Research Institute; Schwarz Pharma; Teva Neuroscience; XenoPort, Inc
Grants/Research Support	Acadia; Allergan Sales, LLC; Berlex Labs; Biogen Idec; Boehringer Ingelheim France; Boston Life Sciences, Inc; Cephalon, Inc; Daiichi Asubio Pharmaceuticals, Inc; Eisai Medical Research, Inc; Elan Pharmaceuticals; GE Healthcare; Genzyme Corporation; GlaxoSmithKline; Kyowa Pharmaceutical, Inc; Mentor Corporation; Merck KgaA; Merz Pharmaceuticals; National Institute of Health; National Institute of Neurological Disorders Stroke; Ovalion Pharmaceuticals; Parkinson's Institute; Schering Plough Research Institute; Skye Pharma, Inc; Solvay Pharmaceuticals; Teva Neuroscience; Vernalis; Vivometrics, Inc; Wellness Pharmaceuticals
Salary	University of South Florida
Speaker's Bureau	Allergan Sales, LLC; Bertek Pharmaceuticals; Boehringer Ingelheim France; GlaxoSmithKline; Norvartis Pharmaceuticals Corporation; Schwarz Pharma; Scienta Healthcare Education; Teva Neuroscience; UCB Pharmaceuticals, Inc; United BioSource Corporation; Vernalis

Resolution of Conflict of Interest (COI)

The EOCME has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public, the EOCME has resolved the conflict by External Content Review.

Financial Support

The EOCME and MedThink Communications, Inc, gratefully acknowledge the educational grant provided by Teva Neuroscience.

Intended Audience

This activity is intended for neurologists involved in the diagnosis and treatment of patients with Parkinson’s disease.

Program Goal

The educational program is designed to introduce neuroprotection as a therapeutic goal in Parkinson's disease (PD) and familiarize participants with the evidence for neuroprotective activity with agents such as monoamine oxidase-B (MAO-B) inhibitors and dopamine agonists.

Educational Objectives

Upon completion of this activity, participants should be able to

• Recognize the importance of neuroprotective treatment in PD
• Describe the neuroprotective mechanisms by which pharmacologic agents stand to modify PD progression
• Explain the evidence for neuroprotective activity of MAO-B inhibitors (eg, rasagiline, selegiline), dopamine agonists (eg, ropinirole, pramipexole), and other agents
• Recognize that early administration of many potential neuroprotective agents is associated with improved clinical outcomes and can delay the need for levodopa treatment
• Discuss advances in PD diagnosis and imaging that allow for earlier administration and assessment of potential neuroprotective therapies

Unapproved/Off-Label Use Disclosure

The EOCME requires CME faculty to disclose to the participants

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Special Needs

We encourage participation by all individuals. If you have any special needs please send an e-mail to info@parkinsonsdiseasecme.com for assistance.